

Market Announcement

28 February 2025

Avecho Biotechnology Limited (ASX: AVE) – Trading Halt

Description

The securities of Avecho Biotechnology Limited ('AVE') will be placed in trading halt at the request of AVE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 3 March 2025 or when the announcement is released to the market.

Issued by

ASX Compliance

28 February 2025

Melissa Kostopoulos
ASX Compliance Pty Limited
Level 4, North Tower
525 Collins Street
Melbourne VIC 3000

(By email: ListingsComplianceMelbourne@asx.com.au)

Dear Melissa,

REQUEST FOR TRADING HALT

Avecho Biotechnology Limited (ASX: AVE) (the **Company**) requests an immediate halt to the trading of the Company's ordinary shares quoted on the Australian Securities Exchange (**ASX**) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending the release of information by the Company to the market in relation to an exclusive license and development agreement (**stated purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make an announcement to the market in relation to the stated purpose above.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Monday, 3 March 2025, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Monday, 3 March 2025.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely,



Melanie Leydin
Company Secretary
Avecho Biotechnology Limited